MARKET

LXRX

LXRX

Lexicon PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.850
-0.070
-2.40%
After Hours: 2.860 +0.01 +0.35% 17:03 02/20 EST
OPEN
2.920
PREV CLOSE
2.920
HIGH
2.975
LOW
2.810
VOLUME
759.78K
TURNOVER
--
52 WEEK HIGH
8.39
52 WEEK LOW
1.125
MARKET CAP
302.87M
P/E (TTM)
2.091
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LXRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LXRX News

  • Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome
  • GlobeNewswire.01/24 20:00
  • Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
  • Benzinga.01/20 23:01
  • Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
  • GlobeNewswire.01/20 21:01
  • Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt?
  • Simply Wall St..01/20 13:07

More

Industry

Biotechnology & Medical Research
+0.09%
Pharmaceuticals & Medical Research
-0.40%

Hot Stocks

Name
Price
%Change

About LXRX

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
More

Webull offers Lexicon Pharmaceuticals, Inc. (LXRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.